Imugene Ltd has released a press release.
Appendix 4E and Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
- Response to ASX Query
- Research partnership with Celularity for solid tumors
- Prospectus for SPP and Placement Options Offer
- Imugene completes $90 M placement and launches $5 M SPP
Later from Imugene
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
- First patient dosed in phase i clinical trial of checkvacc
- Investor Presentation Imugene Eureka Therapeutics
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene